Cargando…
Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era
PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic. RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence sug...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102148/ https://www.ncbi.nlm.nih.gov/pubmed/33961122 http://dx.doi.org/10.1007/s11886-021-01501-7 |
_version_ | 1783689072493985792 |
---|---|
author | Borgaonkar, Sanket Hahn, Joshua Daher, Marilyne Kayani, Waleed Jneid, Hani |
author_facet | Borgaonkar, Sanket Hahn, Joshua Daher, Marilyne Kayani, Waleed Jneid, Hani |
author_sort | Borgaonkar, Sanket |
collection | PubMed |
description | PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic. RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence suggesting that COVID-19 increases the risk of acute coronary syndromes (ACS). SUMMARY: We propose characterizing ACS patients into 3 distinct categories to better assist in appropriate triage and management: critically ill patients, non-critically ill ST elevation myocardial infarction (STEMI) patients, and non-critically ill non-ST elevation myocardial infarction (NSTEMI)/unstable angina (UA) patients. We thoroughly review treatments strategies, management considerations, and current consensus statements for the care of COVID-19 patients with ACS. As we continue to gain more experience with management of COVID-19 in ACS patients and as health-care workers and patients continue to get vaccinated, we must continue to adapt our strategies to treat this high-risk group of patients. |
format | Online Article Text |
id | pubmed-8102148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-81021482021-05-07 Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era Borgaonkar, Sanket Hahn, Joshua Daher, Marilyne Kayani, Waleed Jneid, Hani Curr Cardiol Rep Management of Acute Coronary Syndromes (H Jneid, Section Editor) PURPOSE OF REVIEW: To identify and address the challenges associated with the care of ACS patients during the coronavirus 2019 pandemic. RECENT FINDINGS: The COVID-19 pandemic has had a considerable global impact with over 2.0 million deaths worldwide so far. There has been considerable evidence suggesting that COVID-19 increases the risk of acute coronary syndromes (ACS). SUMMARY: We propose characterizing ACS patients into 3 distinct categories to better assist in appropriate triage and management: critically ill patients, non-critically ill ST elevation myocardial infarction (STEMI) patients, and non-critically ill non-ST elevation myocardial infarction (NSTEMI)/unstable angina (UA) patients. We thoroughly review treatments strategies, management considerations, and current consensus statements for the care of COVID-19 patients with ACS. As we continue to gain more experience with management of COVID-19 in ACS patients and as health-care workers and patients continue to get vaccinated, we must continue to adapt our strategies to treat this high-risk group of patients. Springer US 2021-05-07 2021 /pmc/articles/PMC8102148/ /pubmed/33961122 http://dx.doi.org/10.1007/s11886-021-01501-7 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Management of Acute Coronary Syndromes (H Jneid, Section Editor) Borgaonkar, Sanket Hahn, Joshua Daher, Marilyne Kayani, Waleed Jneid, Hani Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era |
title | Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era |
title_full | Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era |
title_fullStr | Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era |
title_full_unstemmed | Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era |
title_short | Invasive Therapies for Acute Coronary Syndromes in the COVID-19 Era |
title_sort | invasive therapies for acute coronary syndromes in the covid-19 era |
topic | Management of Acute Coronary Syndromes (H Jneid, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102148/ https://www.ncbi.nlm.nih.gov/pubmed/33961122 http://dx.doi.org/10.1007/s11886-021-01501-7 |
work_keys_str_mv | AT borgaonkarsanket invasivetherapiesforacutecoronarysyndromesinthecovid19era AT hahnjoshua invasivetherapiesforacutecoronarysyndromesinthecovid19era AT dahermarilyne invasivetherapiesforacutecoronarysyndromesinthecovid19era AT kayaniwaleed invasivetherapiesforacutecoronarysyndromesinthecovid19era AT jneidhani invasivetherapiesforacutecoronarysyndromesinthecovid19era |